Do all Women Need Testosterone in Menopause? Urologist Breaks Down the Science

Testosterone for Women in Menopause: What the Science Actually Supports

Testosterone therapy for women is one of the most rapidly evolving areas in hormone medicine, and it is also one of the most confusing. The messaging ranges from enthusiastic promotion ("every menopausal woman needs testosterone!") to blanket dismissal ("testosterone is a male hormone with no role in women's health"). Dr. Rena Malik, a board-certified urologist, cuts through both extremes in this video to examine what the scientific evidence actually supports regarding testosterone use in menopausal women.

The question in the title is deliberately provocative: do ALL women need testosterone in menopause? Spoiler alert: the answer is no. But that does not mean testosterone has no role. The nuance between "everyone needs it" and "it helps specific women with specific symptoms" is where the real clinical value lies.

Testosterone Biology in Women

Women produce testosterone throughout their lives, primarily from the ovaries and adrenal glands. The amounts are much smaller than male production (roughly 5 to 10 percent of male levels), but testosterone plays important roles in female physiology. It contributes to libido, energy, muscle maintenance, bone density, and cognitive function. It also is a precursor for estradiol production in various tissues.

Testosterone levels in women decline gradually starting in the late 20s, dropping to approximately half of peak levels by menopause. After menopause, the ovaries continue producing some testosterone (unlike estrogen production, which drops dramatically), but the total output is lower. The adrenal glands continue contributing, but adrenal function also declines with age.

This gradual decline means that by the time a woman reaches menopause, she may have been living with progressively lower testosterone for 15 to 20 years. For some women, this decline is asymptomatic. For others, it contributes to low libido, fatigue, reduced motivation, difficulty building or maintaining muscle, and cognitive changes that overlap with and compound the effects of estrogen decline.

The Evidence for Testosterone Therapy in Women

The strongest evidence for testosterone therapy in women is for hypoactive sexual desire disorder (HSDD), a condition characterized by persistent low sexual desire that causes personal distress. Multiple randomized controlled trials have shown that transdermal testosterone at physiological doses modestly but significantly improves sexual desire, arousal, and satisfaction in postmenopausal women. The Global Consensus Position Statement on testosterone therapy for women, published in 2019, endorsed this indication specifically.

The evidence for other indications is less robust but growing. Observational studies and smaller trials suggest benefits for fatigue, mood, cognitive function, and body composition, but the data is not yet strong enough for these to be considered established indications. This does not mean the benefits do not exist. It means the research has not yet caught up to the clinical observations.

Dosing in women is critically different from dosing in men. The therapeutic dose for women is approximately one-tenth to one-twentieth of the male dose. Most women use 0.5 to 2mg per day of transdermal testosterone, aiming for testosterone levels in the upper half of the premenopausal female reference range. Supraphysiological dosing in women produces virilizing side effects including deepening of the voice, facial hair growth, and clitoral enlargement, some of which may be irreversible.

The Challenges of Testosterone Therapy for Women

One of the biggest challenges is the lack of FDA-approved testosterone products for women. The testosterone products available (gels, creams, pellets, injections) are all designed for men and must be used off-label in significantly reduced doses. This creates issues with dosing accuracy, as cutting a male dose down to a fraction of its intended amount introduces variability. Compounding pharmacies can create women-specific formulations, but the quality and consistency of compounded products vary between pharmacies.

Monitoring testosterone levels in women requires a sensitive assay. Standard testosterone tests used for men are not accurate at the low levels relevant to female physiology. The LC/MS/MS (liquid chromatography with tandem mass spectrometry) assay is the gold standard for measuring testosterone in women and should be specified when ordering labs.

Long-term safety data for testosterone therapy in women is limited. While the short-term safety profile appears favorable (particularly for transdermal delivery at physiological doses), studies longer than 2 years are scarce. Questions about breast cancer risk, cardiovascular effects, and liver health over decades of use remain unanswered. This uncertainty is not a reason to deny treatment to women who would benefit, but it is a reason for ongoing monitoring and honest communication about what we do and do not know.

Who Actually Benefits and How to Tell

The women most likely to benefit from testosterone therapy are those with symptoms consistent with androgen deficiency (low libido, fatigue, reduced motivation, difficulty with muscle and energy) who have already optimized estrogen and progesterone replacement and are still symptomatic. Testosterone should not be the first intervention. It should be added when conventional HRT alone is not addressing all symptoms.

A trial period of 3 to 6 months at physiological doses is the standard approach. If symptoms improve, the therapy is continued with ongoing monitoring. If there is no improvement after 6 months at adequate blood levels, the testosterone should be discontinued. Not every woman responds, and continuing an intervention that is not producing benefits only adds unnecessary medication and cost.

Bloodwork before starting should include total testosterone, free testosterone (by equilibrium dialysis or calculated), SHBG, and DHEA-S. These levels help establish a baseline and guide dosing decisions. Follow-up labs at 6 to 8 weeks confirm that levels are in the therapeutic range and not supraphysiological.

Who Should Watch This

This video is essential viewing for menopausal and perimenopausal women who are experiencing symptoms that estrogen and progesterone alone have not fully addressed. It is also valuable for women who have been offered testosterone by a provider and want to understand the evidence behind the recommendation. Healthcare providers who are uncertain about when and how to prescribe testosterone for women will find Dr. Malik's evidence-based approach a useful reference. Partners of menopausal women who are trying to understand treatment options would also benefit from this balanced presentation.

Navigating the Marketing vs. Medicine Divide

The testosterone therapy space for women has a marketing problem. On one side, you have wellness clinics and social media influencers promoting testosterone as a miracle hormone that every menopausal woman needs. On the other side, you have conservative medical establishments that dismiss testosterone as unproven or dangerous for women. Neither extreme reflects the actual evidence, which shows that testosterone therapy benefits a specific subset of women with specific symptoms when used at appropriate doses with proper monitoring.

The marketing pressure can be particularly intense with pellet therapy clinics, some of which use high doses that push women into supraphysiological ranges. While these doses can produce dramatic short-term improvements in energy and libido, they carry real risks of virilization and long-term side effects that are not always adequately disclosed. Any provider who promises that every woman will benefit from testosterone, who dismisses side effect concerns, or who does not monitor blood levels regularly is not practicing evidence-based medicine, regardless of how confident their marketing sounds.

The evidence-based approach Dr. Malik presents is more measured and ultimately more trustworthy. She acknowledges where the evidence is strong (HSDD in postmenopausal women), where it is promising but incomplete (energy, mood, cognition), and where significant gaps remain (long-term safety, optimal dosing protocols, cardiovascular effects). This honesty is exactly what patients need to make informed decisions. It may be less exciting than a promise of transformation, but it is more likely to result in treatment that is safe, effective, and sustainable.

If you are a woman considering testosterone therapy, bring the framework from this video to your provider conversations. Ask about the evidence for your specific symptoms. Ask about the monitoring plan. Ask about what to expect in terms of timeline and magnitude of benefit. Ask about what happens if it does not work. These questions will help you distinguish between providers who are practicing medicine and providers who are running a business, and that distinction matters enormously for your health outcomes.

The answer to whether all women need testosterone in menopause is clearly no. But the answer to whether some women benefit meaningfully from it is equally clearly yes. The goal is to figure out which category you fall into through careful evaluation, honest conversation with a knowledgeable provider, and a willingness to try treatment when it is indicated while also being willing to stop if it is not helping.

The broader takeaway from this video is that women's hormonal health deserves the same level of attention, research funding, and clinical sophistication that men's hormonal health receives. Testosterone therapy for women is decades behind testosterone therapy for men in terms of research, FDA-approved products, provider education, and public awareness. The fact that there is still no FDA-approved testosterone product for women, despite clear evidence of benefit in specific populations, reflects a systemic gap that patients, providers, and researchers are all working to close.

In the meantime, women who suspect they may benefit from testosterone therapy need to advocate for themselves, seek out knowledgeable providers, and approach the decision with both optimism about the potential benefits and realistic expectations about the current limitations of the evidence. Dr. Malik's video provides the scientific foundation for that approach, and it does so with the balance and rigor that this important topic deserves.